Search Results - "Batlevi CL"

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.

Authors: Merrill MH Redd RA Lambert N et al.

Source: HemaSphere [Hemasphere] 2025 Nov 18; Vol. 9 (11), pp. e70253. Date of Electronic Publication: 2025 Nov 18 (Print Publication: 2025).

Publication Type: Letter

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Authors: Matasar M Li Z Vassilakopoulos TP et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 06, pp. JCO2502849. Date of Electronic Publication: 2026 Jul 06.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy.

Authors: Escribano-Serrat S Shah N Einarsdottir S et al.

Source: Transplantation and cellular therapy [Transplant Cell Ther] 2026 May; Vol. 32 (5), pp. 548.e1-548.e4. Date of Electronic Publication: 2025 Nov 01.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE; In Process

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Authors: Budde LE Kamdar M Assouline SE et al.

Source: Blood [Blood] 2026 Apr 21. Date of Electronic Publication: 2026 Apr 21.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.

Authors: Yamshon S Koff JL Larson MC et al.

Source: American journal of hematology [Am J Hematol] 2025 Apr; Vol. 100 (4), pp. 606-615. Date of Electronic Publication: 2025 Feb 07.

Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.

Authors: Gao L Kallam A Shouse G et al.

Source: Blood advances [Blood Adv] 2025 Dec 23; Vol. 9 (24), pp. 6425-6431.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Authors: Budde LE Zhang H Kim WS et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 20; Vol. 43 (36), pp. 3799-3811. Date of Electronic Publication: 2025 Oct 02.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Authors: Morschhauser F Salles G Sehn LH et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 10; Vol. 43 (35), pp. 3698-3705. Date of Electronic Publication: 2025 Sep 24.

Publication Type: Journal Article; Multicenter Study; Comparative Study; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.

Authors: Ptashkin RN Ewalt MD Jayakumaran G et al.

Source: Nature communications [Nat Commun] 2023 Oct 28; Vol. 14 (1), pp. 6895. Date of Electronic Publication: 2023 Oct 28.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

Authors: Qualls D Noy A Straus D et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 738-741. Date of Electronic Publication: 2023 Jan 15.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

Authors: Lenz G Tilly H Ziepert M et al.

Source: Leukemia [Leukemia] 2024 Dec; Vol. 38 (12), pp. 2709-2711. Date of Electronic Publication: 2024 Sep 25.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE; In Process

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.

Authors: Erazo T Evans CM Zakheim D et al.

Source: Nature communications [Nat Commun] 2022 Sep 27; Vol. 13 (1), pp. 5676. Date of Electronic Publication: 2022 Sep 27.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.

Authors: Sha F Okwali M Alperovich A et al.

Source: Blood cancer journal [Blood Cancer J] 2022 Feb 10; Vol. 12 (2), pp. 29. Date of Electronic Publication: 2022 Feb 10.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Authors: Epstein-Peterson ZD Drill E Aypar U et al.

Source: Haematologica [Haematologica] 2024 Aug 01; Vol. 109 (8), pp. 2749-2752. Date of Electronic Publication: 2024 Aug 01.

Publication Type: Letter; Published Erratum

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Authors: Epstein-Peterson ZD Drill E Aypar U et al.

Source: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1149-1162. Date of Electronic Publication: 2024 Apr 01.

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.

Authors: Bobillo S Joffe E Sermer D et al.

Source: Blood cancer journal [Blood Cancer J] 2021 Jun 16; Vol. 11 (6), pp. 113. Date of Electronic Publication: 2021 Jun 16.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

A closer look at tazemetostat.

Authors: Batlevi CL; Memorial Sloan Kettering Cancer Center New York, New York.

Source: Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2020 Dec; Vol. 18 (12), pp. 820-822.

Publication Type: Interview

Journal Info: Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.

Authors: Wudhikarn K Palomba ML Pennisi M et al.

Source: Blood cancer journal [Blood Cancer J] 2020 Aug 05; Vol. 10 (8), pp. 79. Date of Electronic Publication: 2020 Aug 05.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.

Authors: Budde LE Olszewski AJ Assouline S et al.

Source: Nature medicine [Nat Med] 2024 Jan; Vol. 30 (1), pp. 229-239. Date of Electronic Publication: 2023 Dec 10.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

Authors: Qualls DA Lambert N Caimi PF et al.

Source: Blood [Blood] 2023 Dec 28; Vol. 142 (26), pp. 2327-2331.

Publication Type: Multicenter Study; Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE